No Data
WuXi AppTec (02126): Deloitte appointed as the new auditor.
Wu & Partners has submitted a resignation as the auditor to the board of directors in an announcement released by WuXi AppTec Group (HKG: 02126), effective from 2024...
National Healthcare Security Administration: Negotiations on healthcare will be held in Beijing next week, with adjusted results expected to be announced next month.
According to CCTV, it was learned from the National Medical Insurance Administration that the on-site negotiation/bidding of the medical insurance catalog for 2024 will be held in Beijing from Sunday (the 27th) to next Wednesday (the 30th) as per the work arrangement. The adjustment results are expected to be announced in November, and the new version of the pharmaceutical catalog will be implemented starting next year. According to the "Work Plan for the Adjustment of the National Medical Insurance Pharmaceutical Catalog in 2024", the seventh adjustment of the national medical insurance pharmaceutical catalog since the establishment of the National Medical Insurance Administration officially started in July. After formal review, expert evaluation, and result confirmation, a total of 162 generic pharmaceuticals have been confirmed to participate in negotiations/bidding.
Guangzhou Municipal Party Committee Financial Office: Promote biomedical enterprises to go public.
Guangzhou Municipal Party Committee Deputy Director of the Financial Office, Wen Keyin, stated at a press conference that next steps will continue to create a favorable environment for venture capital development, nurture and strengthen patient capital, guide venture capital institutions to accurately meet the financing needs of biomedical enterprises; focus on the growth characteristics and financing needs of biomedical enterprises, carry out efficient incubation, production-financing matching, and listing cultivation work; continue to promote the integration of insurance institutions in Guangzhou with the characteristics of the biomedical industry, increase research and development efforts for medical instruments, biomedical products, etc. Specific measures include guiding venture capital and venture capital to support the long-term development of the biomedical industry, and increasing support for biomedical
Express News | National Medical Products Administration: Deploys pilot work on segmented production reform of biological products.
Sudden Movement Spotlight | Biomedical Class B shares rose in the afternoon, LKYG-B up 30%, institutions bullish on sector further recovery space
Biomedical Class B shares rose in the afternoon, as of the time of publication, Lai Kai Medicine-B rose by 27.88%, to 7.89 Hong Kong dollars; YimingAngke-B rose by 17.91%, to 5.86 Hong Kong dollars; Yasheng Medicine-B rose by 5.74%, to 46.95 Hong Kong dollars.
WuXi AppTec (02126.HK): BeiNuoDa's commercialization is progressing smoothly, with the potential for continuous expansion of indications space.
According to the company announcement, the recent situation of the company: 1H24 Beinuoda (rituximab injection, relma-cel) has been successfully commercialized, and in August, it was approved domestically for r/r MCL indication. In addition, relma-cel previously
No Data
No Data